Balanced news tone
News Sentiment
BCDA sentiment intelligence
Biocardia Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
87/100 classification confidence.
directly relevant articles
high-authority source matches
-9.7% over one week, -14.6% over four weeks, trend inactive, and below fair value.
BioCardia (BCDA) CEO Peter Altman purchases 500 shares in July 17 trade
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
BioCardia (BCDA) CEO adds 2,300 shares in open-market buys
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 12:00
- Source
- GlobeNewswire
BioCardia says Japan filing, U.S. trial enrollment top 2026 priorities
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
BioCardia Announces $4.4 Million Financing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 12:00
- Source
- GlobeNewswire
BioCardia (NASDAQ: BCDA) extends cash runway with $4.4M equity raise
- Tone
- Positive 66/100
- Event
- Balance sheet
- Published
- 08 Jun 2026 07:00
- Source
- Stock Titan
BioCardia $4.4M raise to extend runway past Japan PMDA submission into 2027
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Stock Titan
BioCardia stock surges on FDA trial pathway confirmation
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- Investing.com
BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 05 Jun 2026 07:00
- Source
- Market source
FDA minutes support BioCardia (NASDAQ: BCDA) CardiAMP HF II PMA pathway
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
BioCardia CEO Peter Altman buys $1,230 in BCDA stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Investing.com
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView